Supriya Lifescience Ltd
SUPRIYASupriya Lifescience Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the P/E sits at the 75th percentile of its own range — the multiple has already done part of the work.
The price is in a confirmed uptrend (7 weeks in) while the P/E sits at the 75th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +48.0% year on year, and 86% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Supriya Lifescience Ltd trades at ₹829, in a confirmed uptrend and 7 weeks into that stage. That is +9.9% against its own 200-day average. It sits at 58% of a 52-week range of ₹577 to ₹1,009. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a confirmed uptrend — week 7 of stage 2, confirmed. At ₹829 it trades +9.9% versus its 200-day average and sits at 58% of its 52-week range (₹577–₹1,009).
Against the market, two honest reads. Cumulative: over the last 4.5 years the stock moved +71% while the NIFTY 500 moved +52% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-10) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 75th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Supriya Lifescience Ltd trades at 32.3× P/E, at the pricey end of its own range (75th percentile). Its long-run median P/E is 26.7×, measured across 4.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 32.3× is at the pricey end of its own range (75th percentile), against a long-run median of 26.7× measured over 4.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +11.3% against a +16.5% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +51.9%/yr price move, ~+32.5%/yr came from earnings growth and ~+19.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Topping out Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Supriya Lifescience Ltd reads as topping out on its fundamental arc. Topping out — profit and EPS growth have decelerated hard (profit growth +56.4% at its peak → +11.2% latest) while ROCE still reads 25.0%. The read is built from 12 quarters across 4 curves, on partial evidence.
Why it matters: decelerating from a peak is where good stories quietly end — the multiple usually notices late.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +19.0% | +21.6% | +16.2% | — |
| Profit | +11.2% | +32.4% | +11.0% | — |
| EPS | +11.3% | +32.5% | +9.0% | — |
| Share price | +16.5% | +51.9% | — | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
61.3/100 — rank 9 of 24 in Pharma - API & CRAMS · 93% evidence confidence
Supriya Lifescience Ltd scores 61.3 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 9. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 16.8 + 19.5 + 13.7 + 11.3 = 61.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Supriya Lifescience Ltd reported ₹277 Cr of revenue in the Mar 26 quarter, +50.5% year on year. That is the 3rd straight quarter of year-on-year growth. Over 9 years it has compounded at 18.2% a year. The last full year, FY26, came in at ₹828 Cr. The last four reported quarters add to ₹828 Cr.
Supriya Lifescience Ltd reported ₹277 Cr of revenue in the Mar 26 quarter, +50.5% year on year. That is the 3rd straight quarter of year-on-year growth. Over 9 years it has compounded at 18.2% a year. The last full year, FY26, came in at ₹828 Cr. The last four reported quarters add to ₹828 Cr.
FY26 revenue came in at ₹828 Cr (+19.0% on the year), capping 9 years at 18.2% compound. The latest quarter (Mar 26) printed ₹277 Cr, +50.5% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +18.0% growth against the decade's 18.2% — the current year is running in line with its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +18.8% over the last 4 quarters against +20.5%/yr over the last 8 — stabilising; TTM profit +11.2% vs +32.0%/yr — rolling over.
→ Revenue grew — did margins hold as it scaled? Next: 35.0% this quarter (−2.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Supriya Lifescience Ltd's operating margin is 35.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 9.0% to 44.0%. The current quarter sits inside that band.
Supriya Lifescience Ltd's operating margin is 35.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 9.0% to 44.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 35.0%, −2.0 pp against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 9.0%–44.0%.
🚨 Why the margin moved: operating margin went −1.4 pp year on year while gross margin went −8.3 pp — the loss came mostly from the gross line: input costs and pricing.
→ Margins slipped — did that reach the bottom line? Next: profit +48.0% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Supriya Lifescience Ltd earned ₹74.0 Cr of net profit in the Mar 26 quarter, +48.0% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹209 Cr. The 9-year compound rate is 48.4%. That is 26.7% of the quarter's revenue. The same quarter a year earlier earned ₹50.0 Cr.
Supriya Lifescience Ltd earned ₹74.0 Cr of net profit in the Mar 26 quarter, +48.0% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹209 Cr. The 9-year compound rate is 48.4%. That is 26.7% of the quarter's revenue. The same quarter a year earlier earned ₹50.0 Cr.
Mar 26 profit was ₹74.0 Cr, +48.0% year on year — the 3rd consecutive quarter of growth. On the full year, FY26 printed ₹209 Cr (+11.2%), and the 9-year compound rate is 48.4%.
Why profit moved: revenue contributed +50.5% and the margin −2.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +10.2% vs revenue +18.0%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
→ Profit rose — but did the cash follow? Next: 86% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 86% of Supriya Lifescience Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was ₹165 Cr of operating cash against ₹188 Cr of profit. After ₹162 Cr of capital spending, ₹3.0 Cr was left as free cash.
FY25: operating cash of ₹165 Cr against reported profit of ₹188 Cr, leaving free cash of ₹3.0 Cr after ₹162 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 86% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 86%: the cash cycle stretched 37 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 7.2× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹459 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Supriya Lifescience Ltd's cash conversion cycle runs 167 days in FY26, up from 130 days in FY21. Capital spending ran ₹459 Cr over the last 3 years. At FY26 sales of ₹828 Cr each day of that cycle holds about ₹2.3 Cr, so roughly ₹379 Cr sits inside the business at any moment.
FY26: debtors at 97 days, inventory at 229 days — roughly 7.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 167 days, looser than FY21's 130.
The full loop: cash goes out to suppliers and production on day 0; stock waits 229 days to sell; customers pay about 97 days after that; and suppliers themselves are paid at 159 days — netting out to the 167-day cycle.
In money terms: at FY26 sales of ₹828 Cr, each day of the cycle holds about ₹2.3 Cr — so the 167-day loop keeps roughly ₹379 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹459 Cr over the last 3 fiscal years against ₹64.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹36.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 25% and the ROIC − WACC spread is +7.2 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Supriya Lifescience Ltd earns a ROCE of 25% in FY26. That is up from a trough of 14% in FY18. Return on invested capital clears the cost of that capital by +7.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 25.2% net margin on 0.61× asset turns.
FY26 ROCE is 25%, recovered from a FY18 trough of 14% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 25.2% net margin × 0.61× asset turns × 1.13× balance-sheet leverage ≈ 17.4% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 19.2% − 12.0% = a +7.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.00.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Supriya Lifescience Ltd carries total debt of ₹5.0 Cr against shareholder equity of ₹1,198 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.04 in FY22 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹5.0 Cr against shareholder equity of ₹1,198 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.04 (FY22) to 0.00 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: Foreign institutions added 1.2 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions added 1.2 points of Supriya Lifescience Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 6.2% of the company. Domestic institutions moved −0.2 points over the same window, to 5.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +1.2 points over 8 quarters to 6.2%; Domestic institutions: −0.2 points over 8 quarters to 5.3%; Promoters: +0.0 points over 8 quarters to 68.3%.
Why the register moved: foreign institutions drove it (+1.2 points) — steady accumulation by institutions reading the same numbers this page reads.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Supriya Lifescience Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Supriya Lifescience Ltd this page | 32.3× | ₹6,765 Cr | Consistent | |||
| Divis Laboratories Ltd | 73.4× | ₹1.9L Cr | Mixed | |||
| Laurus Labs Ltd | 79.1× | ₹86,505 Cr | Mixed | |||
| Anthem Biosciences Ltd | 73.1× | ₹43,360 Cr | No read | |||
| Gland Pharma Ltd | 37.6× | ₹39,257 Cr | Improving | |||
| Acutaas Chemicals Ltd | 75.2× | ₹26,785 Cr | Improving | |||
| Acutaas Chemicals Ltd | 69.1× | ₹26,686 Cr | Mixed | |||
| Sai Life Sciences Ltd | 73.8× | ₹26,174 Cr | No read | |||
| Piramal Pharma Ltd | — | ₹24,133 Cr | No read | |||
| Neuland Laboratories Ltd | 65.9× | ₹23,794 Cr | Turning around | |||
| Granules India Ltd | 31.8× | ₹20,655 Cr | Consistent | |||
| OneSource Specialty Pharma Ltd | — | ₹18,961 Cr | No read | |||
| Syngene International Ltd | 44.9× | ₹16,708 Cr | Turning around | |||
| Syngene International Ltd | 44.1× | ₹16,415 Cr | Turning around | |||
| Cohance Lifesciences Ltd | 80.9× | ₹15,957 Cr | Deteriorating | |||
| Jubilant Pharmova Ltd | 35.2× | ₹15,378 Cr | No read | |||
| Concord Biotech Ltd | 54.8× | ₹13,061 Cr | Deteriorating | |||
| Shilpa Medicare Ltd | 50.8× | ₹11,856 Cr | No read | |||
| Blue Jet Healthcare Ltd | 43.3× | ₹10,730 Cr | Deteriorating | |||
| IOL Chemicals & Pharmaceuticals Ltd | 30.0× | ₹4,380 Cr | Improving | |||
| SMS Pharmaceuticals Ltd | 35.0× | ₹3,569 Cr | Mixed | |||
| Morepen Laboratories Ltd | 39.6× | ₹2,948 Cr | Mixed | |||
| Dishman Carbogen Amcis Ltd | 29.0× | ₹2,878 Cr | No read | |||
| Hikal Ltd | 73.8× | ₹2,681 Cr | Deteriorating | |||
| Solara Active Pharma Sciences Ltd | 551.0× | ₹2,351 Cr | No read | |||
| Windlas Biotech Ltd | 26.6× | ₹1,770 Cr | Mixed |
Frequently asked questions
What is Supriya Lifescience Ltd's share price today?
Supriya Lifescience Ltd trades at ₹829, +16.5% over the past year. The company is valued at ₹6,765 Cr. The stock sits at 58% of its 52-week range of ₹577–₹1,009, +9.9% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 7 weeks in. — as of 24 July 2026.
What were Supriya Lifescience Ltd's latest quarterly results?
Supriya Lifescience Ltd reported revenue of ₹277 Cr and net profit of ₹74.0 Cr for the Mar 26 quarter. Revenue rose 50.5% and profit rose 48.0% year on year. Earnings per share were ₹9.22. The operating margin was 35.0%, 2.0 pp lower than a year earlier. — as of 24 July 2026.
What is Supriya Lifescience Ltd's revenue?
Supriya Lifescience Ltd reported revenue of ₹277 Cr in the Mar 26 quarter, +50.5% year on year. For the full FY26 fiscal year, revenue was ₹828 Cr (+19.0%). Over the last 9 years revenue compounded at 18.2% a year. — as of 24 July 2026.
What is Supriya Lifescience Ltd's profit?
Supriya Lifescience Ltd earned ₹74.0 Cr of net profit in the Mar 26 quarter, +48.0% year on year — the 3rd straight quarter of growth. Full-year FY26 profit was ₹209 Cr. The operating margin ran 35.0% in the latest quarter. — as of 24 July 2026.
What is Supriya Lifescience Ltd's market cap?
Supriya Lifescience Ltd's market capitalisation is ₹6,765 Cr at a share price of ₹829. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Supriya Lifescience Ltd's P/E ratio?
Supriya Lifescience Ltd trades at a P/E of 32.3×, at the 75th percentile of its own 5-year range, against a long-run median of 26.7×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Supriya Lifescience Ltd pay a dividend?
Yes — Supriya Lifescience Ltd's dividend payout was 4% of profit in FY26, and it recorded a payout in 7 of its last 10 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Supriya Lifescience Ltd overvalued?
On its own history, Supriya Lifescience Ltd looks expensive against its own history: its P/E of 32.3× sits at the 75th percentile of its 5-year range (long-run median 26.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Supriya Lifescience Ltd growing?
Yes — Supriya Lifescience Ltd is growing: latest-quarter revenue +50.5% year on year, profit +48.0%, and the margin −2.0 pp at 35.0%. The 9-year compound rates are 18.2% (revenue) and 48.4% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Supriya Lifescience Ltd performing?
Supriya Lifescience Ltd is in a confirmed uptrend, 7 weeks in. Its latest quarter's revenue rose 50.5% and profit rose 48.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Supriya Lifescience Ltd in?
Topping out — profit and EPS growth have decelerated hard (profit growth +56.4% at its peak → +11.2% latest) while ROCE still reads 25.0%. The read comes from the last 12 quarters of growth (revenue growth +18.8% latest, profit growth +11.2% latest, eps growth +11.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Supriya Lifescience Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 7 of stage 2), trading +9.9% versus its 200-day average and at 58% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Supriya Lifescience Ltd beating the market?
Not lately — on a trailing-13-week view Supriya Lifescience Ltd is currently behind the NIFTY 500 (1 week and counting; last ahead the week of 2026-07-10), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 4.5 years the stock moved +71% against the NIFTY 500's +52% — ahead of the index over the full window. — as of 24 July 2026.
Will Supriya Lifescience Ltd's share price go up?
This page publishes no price forecast for Supriya Lifescience Ltd. What it measures instead: the share price is ₹829, the price is in a confirmed uptrend 7 weeks in. Its P/E of 32.3× sits at the 75th percentile of its own 5-year range. — as of 24 July 2026.
Who owns Supriya Lifescience Ltd?
Promoters hold 68.3% of Supriya Lifescience Ltd, foreign institutions 6.2%, domestic institutions 5.3% and the public 20.2% (latest quarter). The biggest move on the register over the last two years: Foreign institutions added 1.2 points over 8 quarters. — as of 24 July 2026.
Does Supriya Lifescience Ltd have too much debt?
No — Supriya Lifescience Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill north of 100×. FY26 borrowings were ₹5.0 Cr against equity of ₹1,198 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Supriya Lifescience Ltd's capex?
Supriya Lifescience Ltd spent ₹459 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹152 Cr, with ₹36.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Supriya Lifescience Ltd's cash flow?
Supriya Lifescience Ltd generated ₹165 Cr of operating cash flow in FY25 and ₹3.0 Cr of free cash flow after ₹162 Cr of capital spending. Reported profit that year was ₹188 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Supriya Lifescience Ltd's profit real cash?
Yes — over the last 3 fiscal years, 86% of Supriya Lifescience Ltd's reported profit arrived as operating cash. In FY25, operating cash was ₹165 Cr against reported profit of ₹188 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Supriya Lifescience Ltd in its business cycle?
Supriya Lifescience Ltd's FY26 operating margin was 36.0%, against a 10-year band of 9.0%–44.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 35.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Supriya Lifescience Ltd story?
Biggest watch item: the P/E sits at the 75th percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Supriya Lifescience Ltd a stock worth studying right now?
This is not investment advice. The machine read: Supriya Lifescience Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.